CD4 and colorectal carcinoma: A fixed-effects meta-analysis of these homogeneous studies indicated a statistically significant increase in CD4+ T cell levels among CRC patients receiving ω-3 PUFA supplementation compared with placebo controls: [MD = 3.49, 95% CI (2.91, 4.06), Z = 11.86, p < 0.00001].